Search Results

1 - 10 of 130 items :

Clear All
Renin Genetic Polymorphism in Heart Failure Patients

References 1. NGUYEN G, MULLER DN. The biology of the (pro) renin receptor. J Am Soc Nephrol. 2010; 21(1):18-23. 2. SCHALEKAMP MA, DERKX FH, DEINUM J, DANSER AJ. Newly developed renin and prorenin assays and the clinical evaluation of renin inhibitors. J Hypertens. 2008; 26(5):928-937. Review. 3. VOLPE M, BATTISTONI A, CHIN D, RUBATTU S, TOCCI G. Renin as a biomarker of cardiovascular disease in clinical practice. Nutr Metab Cardiovasc Dis. 2012; 22 (4):312-317. 4. DICKSTEIN K, COHEN-SOLAL A

Open access
Correlation of Salt Sensitivity, Plasma Renin Activity and Aldosterone in Hypertensive Patients

References 1. Williams GH, Dluhy RG, Lifton RP, Moore TJ, Gleason R, Williams R, Hunt SC, Hopkins PN, Hollenberg NK. Non-modulation as an intermediate phenotype in essential hypertension. Hypertension. 1992 Dec;20(6):788-96. 2. Sealey JE, Blumenfeld JD, Bell GM, Pecker MS, Sommers SC, Laragh JH. On the renal basis of essential hypertension. Nephron heterogeneity with discordant renin secretion and sodium excretion causing a hypertensive vasoconstriction-volume relationship. Kidney Int 1988;34(Supp1 25):S64-S7. 3

Open access
Effect of Dual Blockade of Renin-Angiotensin System on Proteinuria

-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993; 329:1456-1462. 8. Kunz R, Friedrich C, Wolbers M, Mann JF. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease.Ann Intern Med. 2008; 148:30-48. 9. Keane WF, Brenner BM, de Zeeuw D, et al. The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study. Kidney Int. 2003; 63:1499-1507. 10. Andersen NH

Open access
The influence of renin angiotensin aldosterone system blockers on asymmetric dimethylarginine levels in patients with chronic glomerulonephritis

(ADMA): an endogenous inhibitor of nitric oxide synthase and a novel cardiovascular risk molecule. Med Sci Monit ., 15, RA91-101, 2009. 5. Deckert T., Feldt-Rasmussen B., Borch-Johnsen K. Albuminuria reflects widespread vascular damage. The Steno hypothesis. Diabetologia , 32, 219-226, 1989. 6. Fliser D. et al. Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study. J Am Soc Nephrol ., 16, 2456-2461, 2005. 7. Fujii H. et al. Renin-Angiotensin System Inhibitors Reduce Serum Asymmetric

Open access
Alternative renin-angiotensin system pathways in adipose tissue and their role in the pathogenesis of obesity

References Achard V, Boullu-Ciocca S, Desbriere R, Nguyen G, Grino M. Renin receptor expression in human adipose tissue. Am J Physiol Regul Integr Comp Physiol 292, R274–282, 2007. Achard V, Tassistro V, Boullu-Ciocca S, Grino M. Expression and nutritional regulation of the (pro)renin receptor in rat visceral adipose tissue. J Endocrinol Invest 34, 840–846, 2011. Albiston AL, McDowall SG, Matsacos D, Sim P, Clune E, Mustafa T, Lee J, Mendelsohn FA, Simpson RJ, Connolly LM, Chai SY. Evidence that the angiotensin IV (AT(4)) receptor is the enzyme

Open access
Renin–angiotensin–aldosterone system in insulin resistance and metabolic syndrome

hypertension. Antihypertensive drugs such as thiazide diuretics and β-blockers adversely affect glucose metabolism and increase the risk of developing type-2 diabetes [ 3 - 6 ] , though this has been disputed [ 7 - 11 ] . On the other hand, drugs that interfere with the renin–angiotensin system (RAS) improve insulin sensitivity, produce a significant decline of albuminuria, induce a drop of the pathological glomerular hyperfiltration, and reduce the incidence of new-onset diabetes [ 12 - 17 ] . Therefore, the initial selection of antihypertensive therapy for obese

Open access
Effects of Interactions among Gene Polymorphisms of the Renin–Angiotensin-Aldosterone System on Hypertension in Turkish People from Southeast Anatolia

-2012-302883 10. Jiang X, Sheng H, Li J, Xun P, Cheng Y, Huang J, et al. Association between renin-angiotensin system gene polymorphism and essential hypertension: a community-based study. J Hum Hypertens. 2009; 23(3):176-81. DOI: 10.1038/jhh.2008.123 11. Zhao J, Qin X, Li S, Zeng Z. Association between the ACE I/D polymorphism and risk of ischemic stroke: an updated meta-analysis of 47,026 subjects from 105 case-control studies. J Neurol Sci. 2014; 345(1-2):37-47. DOI: 10.1016/j.jns.2014.07.023 12. Niu W, Qi Y, Hou S, Zhai X, Zhou W, Qiu C

Open access
Prognostic value of soluble angiotensin II receptor 1 and soluble angiotensin converting enzyme (CD 143) in patients with acute leukemia

Introduction There is increasing evidence that angiotensin II (Ang II), a major regulator of blood pressure and cardiovascular homeostasis, is involved in the regulation of cell proliferation, angiogenesis, inflammation and tissue remodeling, which suggests that this peptide might also play a role in cancer [ 1 ]. The renin-angiotensin system (RAS) has been characterized extensively in hypertension and atherosclerosis, but recently its relevance to the fields of oncology and hematology are being studied [ 2 , 3 ]. The RAS pathway mediates its effect

Open access
Primary Aldosteronism in a Patient with Autosomal Dominant Polycystic Kidney Disease Associated with Polycystic Liver Disease

. 2011 Jan;7(1):55. DOI: 10.1038/nrneph.2010.158 16. Kao C-C, Wu V-C, Kuo C-C, Lin Y-H, Hu Y-H, Tsai Y-C, et al. Delayed diagnosis of primary aldosteronism in patients with autosomal dominant polycystic kidney diseases. Journal of the Renin-Angiotensin-Aldosterone System. 2013;14(2):167-73. DOI: 10.1177/1470320312452767 17. Torres VE, Young Jr WF. Offord KP. Hattery RR: Association of hypokalemia, aldosteronism, and renal cysts. N EngI J Med. 1990;322:345-51. doi:10.1056/NEJM199002083220601 18. Torres VE, Donovan KA, Scicli G, Holley KE, Thibodeau SN

Open access
Effects Of The Direct Renin Inhibitor Aliskiren On Oxidative Stress In Isolated Rat Heart

ABBREVIATIONS ACEI - Angiotensin converting enzyme inhibitors ARB - Angiotensin receptor blockers AT - Angiotensin CF - Coronary flow cGMP - Cyclic guanosine 3′,5′-monophosphate DRI - Direct renin inhibitor MDA – Malondialdehyde NO - Nitric oxide RAAS - Renin-angiotensin-aldosterone system ROS - Reactive oxygen species REFERENCES 1. Angeli F, Reboldi G, Mazzotta G, et al. Safety and efficacy of aliskiren in the treatment of hypertension and associated clinical conditions. Curr Drug Saf. 2012;7(1):76-85. 2. Dzau V. The

Open access